Cyproheptadine (CPH) is a histamine- and serotonin-receptor antagonist, and its effects are observed recently in the modulation of multiple intracellular signals. In this study, we used cortical neurons and HEK-293 cells transfected with Kv2.1 α-subunit to address whether CPH modify neural voltage-gated K+ channels by a mechanism independent of its serotonergic and histaminergic properties. Our results demonstrate that intracellularly delivered CPH increased the IK by reducing the activity of protein kinas A (PKA). Inhibition of Gi eliminated the CPH-induced effect on both the IK and PKA. Blocking of 5-HT-, M-, D2-, H1- or H2- type GPCR receptors with relevant antagonists did not eliminate the CPH-induced effect on the IK. Antagonists of the sigma-1 receptor, however, blocked the effect of CPH. Moreover, the inhibition of sigma-1 by siRNA knockdown significantly reduced the CPH-induced effect on the IK. On the contrary, sigma-1 receptor agonist mimicked the effects of CPH on the induction of IK. A ligand-receptor binding assay indicated that CPH bound to the sigma-1 receptor. Similar effect of CPH were obtained from HEK-293 cells transfected with the α-subunit of Kv2.1. In overall, we reveal for the first time that CPH enhances the IK by modulating activity of PKA, and that the associated activation of the sigma-1 receptor/Gi-protein pathway might be involved. Our findings illustrate an uncharacterized effect of CPH on neuron excitability through the IK, which is independent of histamine H1 and serotonin receptors.
References
[1]
Droogmans S, Roosens B, Cosyns B, Degaillier C, Hernot S, et al. (2009) Cyproheptadine prevents pergolide-induced valvulopathy in rats: an echocardiographic and histopathological study. Am J Physiol Heart Circ Physiol 296: H1940–1948.
[2]
Spangler DL, Brunton S (2006) Efficacy and central nervous system impairment of newer-generation prescription antihistamines in seasonal allergic rhinitis. South Med J 99: 593–599.
[3]
Goudie AJ, Cooper GD, Cole JC, Sumnall HR (2007) Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats. J Psychopharmacol 21: 179–190.
[4]
Wooltorton JR, Mathie A (1995) Potent block of potassium currents in rat isolated sympathetic neurones by the uncharged form of amitriptyline and related tricyclic compounds. Br J Pharmacol 116: 2191–2200.
[5]
Remy DC, Raab AW, Rittle KE, Engelhardt EL, Scriabine A, et al. (1977) A comparison of the antiserotonin, antihistamine, and anticholinergic activity of cyproheptadine with analogues having furan nuclei fused to the 10,11-vinylene bridge. J Med Chem 20: 836–838.
[6]
Kotake H, Saitoh M, Ogino K, Hirai S, Matsuoka S, et al. (1987) On the ionic mechanism of cyproheptadine-induced bradycardia in a rabbit sinoatrial node preparation. Eur J Pharmacol 139: 307–313.
[7]
Mao X, Liang SB, Hurren R, Gronda M, Chow S, et al. (2008) Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood 112: 760–769.
[8]
Codd EE, Baker J, Brandt MR, Bryant S, Cai C, et al. (2010) Diabetogenic effect of a series of tricyclic delta opioid agonists structurally related to cyproheptadine. Toxicol Sci 117: 493–504.
[9]
Hawkins BS, Fischer LJ (2004) Inhibition of insulin synthesis by cyproheptadine: effects on translation. Toxicol Sci 79: 258–265.
[10]
Pal A, Hajipour AR, Fontanilla D, Ramachandran S, Chu UB, et al. (2007) Identification of regions of the sigma-1 receptor ligand binding site using a novel photoprobe. Mol Pharmacol 72: 921–933.
[11]
Walker, J M, Bowen, W D, Walker, F O, Matsumoto, R R, De Costa, B. and Rice, K C (1990) Sigma receptors: biology and function. Pharmacol Rev. 42, 355–402.
[12]
Melishchuk A, Loboda A, Armstrong CM (1998) Loss of shaker K channel conductance in 0K+ solutions: role of the voltage sensor. Biophys J 75: 1828–1835.
[13]
Mathie A, Wooltorton JR, Watkins CS (1998) Voltage-activated potassium channels in mammalian neurons and their block by novel pharmacological agents. Gen Pharmacol 30: 13–24.
[14]
Wulff H, Castle NA, Pardo LA (2009) Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov 8: 982–1001.
[15]
Liu LY, Hoffman GE, Fei XW, Li Z, Zhang ZH, et al. (2007) Delayed rectifier outward K+ current mediates the migration of rat cerebellar granule cells stimulated by melatonin. J Neurochem 102: 333–344.
[16]
Misonou H, Mohapatra DP, Park EW, Leung V, Zhen D, et al. (2004) Regulation of ion channel localization and phosphorylation by neuronal activity. Nat Neurosci 7: 711–718.
[17]
Suh HW, Chung KM, Kim YH, Huh SO, Song DK (1999) Effects of histamine receptor antagonists injected intrathecally on antinociception induced by opioids administered intracerebroventricularly in the mouse. Neuropeptides 33: 121–129.
[18]
Klouz A, Sapena R, Liu J, Maurice T, Tillement JP, et al. (2002) Evidence for sigma-1-like receptors in isolated rat liver mitochondrial membranes. Br J Pharmacol 135: 1607–1615.
[19]
Du J, Haak LL, Phillips-Tansey E, Russell JT, McBain CJ (2000) Frequency-dependent regulation of rat hippocampal somato-dendritic excitability by the K+ channel subunit Kv2.1. J Physiol 522 Pt 1: 19–31.
[20]
He YL, Zhan XQ, Yang G, Sun J, Mei YA (2010) Amoxapine inhibits the delayed rectifier outward K+ current in mouse cortical neurons via cAMP/protein kinase A pathways. J Pharmacol Exp Ther 332: 437–445.
[21]
Freissmuth M, Boehm S, Beindl W, Nickel P, Ijzerman AP, et al. (1996) Suramin analogues as subtype-selective G protein inhibitors. Mol Pharmacol 49: 602–611.
[22]
Cerda O, Trimmer JS (2011) Activity-dependent phosphorylation of neuronal Kv2.1 potassium channels by CDK5. J Biol Chem 286: 28738–28748.
[23]
Clineschmidt BV, Hanson HM, McGuffin JC, Lotti VJ, Scriabine A, et al. (1976) Appetite stimulant activity of 3-carboxy-10,11-dihydrocyproheptadine. Arch Int Pharmacodyn Ther 223: 287–300.
[24]
Holl R, Geiger C, Nambo M, Itami K, Schepmann D, et al. (2009) Structure-affinity-relationship study of bicyclic sigma receptor ligands. Cent Nerv Syst Agents Med Chem 9: 220–229.
[25]
Hayashi T, Su TP (2004) Sigma-1 receptors at galactosylceramide-enriched lipid microdomains regulate oligodendrocyte differentiation. Proc Natl Acad Sci U S A 101: 14949–14954.
[26]
Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, et al. (1996) Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci U S A 93: 8072–8077.
[27]
Soriani O, Foll FL, Roman F, Monnet FP, Vaudry H, et al. (1999) A-Current down-modulated by sigma receptor in frog pituitary melanotrope cells through a G protein-dependent pathway. J Pharmacol Exp Ther 289: 321–328.
[28]
Kim FJ, Kovalyshyn I, Burgman M, Neilan C, Chien CC, et al. (2010) Sigma 1 receptor modulation of G-protein-coupled receptor signaling: potentiation of opioid transduction independent from receptor binding. Mol Pharmacol 77: 695–703.
[29]
Levitt ES, Purington LC, Traynor JR (2010) Gi/o-coupled receptors compete for signaling to adenylyl cyclase in SH-SY5Y cells and reduce opioid-mediated cAMP overshoot. Mol Pharmacol 79: 461–471.
[30]
Zhang H, Cuevas J (2005) sigma Receptor activation blocks potassium channels and depresses neuroexcitability in rat intracardiac neurons. J Pharmacol Exp Ther 313: 1387–1396.
[31]
Aydar E, Palmer CP, Klyachko VA, Jackson MB (2002) The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 34: 399–410.
[32]
Tchedre KT, Huang RQ, Dibas A, Krishnamoorthy RR, Dillon GH, et al. (2008) Sigma-1 receptor regulation of voltage-gated calcium channels involves a direct interaction. Invest Ophthalmol Vis Sci 49: 4993–5002.
[33]
Renaudo A, L’Hoste S, Guizouarn H, Borgese F, Soriani O (2007) Cancer cell cycle modulated by a functional coupling between sigma-1 receptors and Cl- channels. J Biol Chem 282: 2259–2267.
[34]
Misonou H, Thompson SM, Cai X (2008) Dynamic regulation of the Kv2.1 voltage-gated potassium channel during brain ischemia through neuroglial interaction. J Neurosci 28: 8529–8538.
[35]
Mohapatra DP, Trimmer JS (2006) The Kv2.1 C terminus can autonomously transfer Kv2.1-like phosphorylation-dependent localization, voltage-dependent gating, and muscarinic modulation to diverse Kv channels. J Neurosci 26: 685–695.
[36]
Jiao S, Liu Z, Ren WH, Ding Y, Zhang YQ, et al. (2007) cAMP/protein kinase A signalling pathway protects against neuronal apoptosis and is associated with modulation of Kv2.1 in cerebellar granule cells. J Neurochem 100: 979–991.
[37]
Mavlyutov TA, Epstein ML, Andersen KA, Ziskind-Conhaim L, Ruoho AE (2010) The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study. Neuroscience 167: 247–255.
[38]
Mavlyutov TA, Epstein ML, Liu P, Verbny YI, Ziskind-Conhaim L, et al. (2012) Development of the sigma-1 receptor in C-terminals of motoneurons and colocalization with the N,N’-dimethyltryptamine forming enzyme, indole-N-methyl transferase. Neuroscience 206: 60–68.
[39]
Liao Z, Yuan C, Peng K, Xiao Y, Liang S (2007) Solution structure of Jingzhaotoxin-III, a peptide toxin inhibiting both Nav1.5 and Kv2.1 channels. Toxicon 50: 135–143.
[40]
Rueff L, Graber JJ, Bernbaum M, Kuzniecky RI (2008) Voltage-gated potassium channel antibody-mediated syndromes: a spectrum of clinical manifestations. Rev Neurol Dis 5: 65–72.
[41]
Wua YJ, Dworetzky SI (2005) Recent developments on KCNQ potassium channel openers. Curr Med Chem 12: 453–460.
[42]
Stahl SM (2005) Antidepressant treatment of psychotic major depression: potential role of the sigma receptor. CNS Spectr 10: 319–323.
[43]
Goueli BS, Hsiao K, Tereba A, Goueli SA (1995) A novel and simple method to assay the activity of individual protein kinases in a crude tissue extract. Anal Biochem 225: 10–17.
[44]
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275.
[45]
Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099–3108.
